AI Article Synopsis

  • A phase I/II study tested combination therapy of carboplatin (CBDCA) and nab-paclitaxel (Nab-PTX) in patients with non-small-cell lung cancer (NSCLC) who had a performance status (PS) of 2.
  • The recommended doses were set as CBDCA at an area under the curve of 6 mg/ml/min and Nab-PTX at 100 mg/m², with 27 patients evaluated in the phase II segment.
  • Findings showed a 44% overall response rate, with median progression-free survival at 5.2 months and overall survival at 14.0 months, indicating this therapy could be a viable option for PS 2 NSCLC patients

Article Abstract

Background/aim: This phase I/II study aimed at assessing the efficacy of combination therapy with carboplatin (CBDCA) on day 1 and nab-paclitaxel (Nab-PTX) on days 1 and 8 of a 21-day cycle in performance status (PS) 2 patients with non-small-cell lung cancer (NSCLC).

Patients And Methods: PS 2 patients with NSCLC were enrolled into a phase I study using a 3 + 3 design. Once the recommended phase II dose (RP2D) was established, the patients were enrolled into phase II.

Results: Based on the phase I findings, the RP2D was determined as CBDCA area under the curve 6 mg/ml/min and Nab-PTX 100 mg/m In the phase II part, 27 patients were evaluable. The overall response rate was 44%. The median progression-free survival and overall survival were 5.2 months and 14.0 months, respectively. There was no treatment-related death.

Conclusion: CBDCA plus Nab-PTX therapy is a promising treatment strategy for PS 2 patients with NSCLC.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13263DOI Listing

Publication Analysis

Top Keywords

performance status
8
status patients
8
non-small-cell lung
8
lung cancer
8
patients nsclc
8
enrolled phase
8
patients
6
phase
6
carboplatin nab-paclitaxel
4
nab-paclitaxel performance
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!